Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
GRF:BME
Grifols SA Class A
8,96 €
+1,63%
(+0,14) 1D
30 apr, 17:36:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GRF...
Açın
8,74 €
High
8,97 €
Low
8,68 €
Mkt. cap
5,52 mlrd
Avg. vol.
2,63 mln
Volume
1,64 mln
Dividend
1,67%
Quarterly dividend
0,04 €
Ex dividend date
11 avq 2025
P/E ratio
15,17
52-wk high
13,70 €
52-wk low
8,01 €
EPS
0,59 €
Shares outstanding
426,13 mln
No. of employees
25K
News stories
From sources across the web
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A
CEONacho Abia
Employees25,3K
Founded18 noy 1940
Headquarters-
Sector-
Websitegrifols.com
Last report
26 fev 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-/ -EUR
Revenue / Estimate
1,98 mlrd/ (1,96 mlrd est.)EUR
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
1,79 mlrd
1,89 mlrd
1,87 mlrd
1,98 mlrd
Cost of goods sold
1,08 mlrd
1,15 mlrd
1,11 mlrd
1,28 mlrd
Cost of revenue
1,08 mlrd
1,15 mlrd
1,11 mlrd
1,28 mlrd
Research and development expenses
96,05 mln
96,19 mln
97,01 mln
90,82 mln
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
315,37 mln
298,06 mln
273,76 mln
262,86 mln
Operating expense
411,42 mln
394,25 mln
370,34 mln
353,11 mln
Total operating expenses
1,49 mlrd
1,54 mlrd
1,48 mlrd
1,63 mlrd
Operating income
293,22 mln
349,54 mln
381,18 mln
347,38 mln
Other non operating income
-
8,08 mln
-
-33,00 mln
EBT including unusual items
115,26 mln
190,51 mln
198,13 mln
111,10 mln
EBT excluding unusual items
134,52 mln
190,51 mln
227,20 mln
183,10 mln
Income tax expense
22,84 mln
52,13 mln
54,71 mln
-14,68 mln
Effective tax rate
19,82%
27,36%
27,61%
-13,21%
Other operating expenses
-
-
-430,00K
-570,00K
Net income
59,72 mln
117,06 mln
126,96 mln
98,25 mln
Net profit margin
3,34%
6,19%
6,81%
4,96%
Earnings per share
-
0,19
-
-
Interest and investment income
-
9,56 mln
-
36,00 mln
Interest expense
-153,59 mln
-141,43 mln
-156,07 mln
-107,99 mln
Net interest expenses
-153,59 mln
-131,88 mln
-156,07 mln
-71,99 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
404,97 mln
414,24 mln
484,03 mln
422,88 mln
Gain or loss from assets sale
-
732,00K
-
2,00 mln
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer